Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ida Kappel Buhl"'
Autor:
Ida Kappel Buhl, Eric Santoni-Rugiu, Jesper Ravn, Anker Hansen, Ib Jarle Christensen, Thomas Jensen, Bruce Pratt, Jon Askaa, Peter Buhl Jensen, Steen Knudsen, Jens Benn Sørensen
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0194609 (2018)
Effective predictive biomarkers for selection of patients benefiting from adjuvant platinum-based chemotherapy in non-small cell lung cancer (NSCLC) are needed. Based on a previously validated methodology, molecular profiles of predicted sensitivity
Externí odkaz:
https://doaj.org/article/fa1ec23de6bb4b5588af6657dd77f122
Autor:
Ida Kappel Buhl, Sarah Gerster, Mauro Delorenzi, Thomas Jensen, Peter Buhl Jensen, Fred Bosman, Sabine Tejpar, Arnaud Roth, Nils Brunner, Anker Hansen, Steen Knudsen
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155123 (2016)
PURPOSE:This study evaluates whether gene signatures for chemosensitivity for irinotecan and 5-fluorouracil (5-FU) derived from in vitro grown cancer cell lines can predict clinical sensitivity to these drugs. METHODS:To test if an irinotecan signatu
Externí odkaz:
https://doaj.org/article/fb47ed7629254f099cdacbcdda19711b
Autor:
Ida Kappel Buhl, Troels Dreier Christensen, Anna Sofie Kappel Buhl, Ib Jarle Christensen, Eva Balslev, Ann Søegaard Knop, Bent Ejlertsen, Iben Kümler, Hella Danø, Adam Andrzej Luczak, Sven Tyge Langkjer, Søren Linnet, Erik Hugger Jakobsen, Jurij Bogovic, Vesna Glavicic, Ulla Hald Buhl, Steen Knudsen, Peter Buhl Jensen, Dorte Nielsen
Background Even with positive oestrogen receptor (ER+) status some advanced breast cancer (ABC) patients fail to benefit from endocrine therapy (ET). A method that previously predicted other drugs in various cancers was evaluated. Here multigene mark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f74f0164074f9f5c285dc7b7b2cb16b
https://doi.org/10.21203/rs.2.10981/v1
https://doi.org/10.21203/rs.2.10981/v1
Publikováno v:
Buhl, I K, Jensen, P B, Buhl, A S K & Knudsen, S 2019, ' A drug response predictor to guide treatment for breast cancer ', Pharmacogenomics, vol. 20, no. 5, pp. 307-310 . https://doi.org/10.2217/pgs-2018-0195
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df365c815e6cbf75b9dc3fd7d508af3a
https://curis.ku.dk/portal/da/publications/a-drug-response-predictor-to-guide-treatment-for-breast-cancer(3ae59a56-8e6d-465e-bf33-9239ecfb882e).html
https://curis.ku.dk/portal/da/publications/a-drug-response-predictor-to-guide-treatment-for-breast-cancer(3ae59a56-8e6d-465e-bf33-9239ecfb882e).html
Autor:
Anker Jon Hansen, Peter Buhl Jensen, Thomas Jensen, Jesper Ravn, Jon Askaa, Steen Knudsen, Eric Santoni-Rugiu, Jens Benn Sørensen, Ib Jarle Christensen, Ida Kappel Buhl, Bruce Pratt
Publikováno v:
Buhl, I K, Santoni Rugiu, E, Ravn, J, Hansen, A, Christensen, I J, Jensen, T, Pratt, B, Askaa, J, Jensen, P B, Knudsen, S & Sørensen, J B 2018, ' Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts ', PLOS ONE, bind 13, nr. 3, e0194609 . https://doi.org/10.1371/journal.pone.0194609
PLoS ONE, Vol 13, Iss 3, p e0194609 (2018)
PLoS ONE
PLoS ONE, Vol 13, Iss 3, p e0194609 (2018)
PLoS ONE
IntroductionEffective predictive biomarkers for selection of patients benefiting from adjuvant platinum-based chemotherapy in non-small cell lung cancer (NSCLC) are needed. Based on a previously validated methodology, molecular profiles of predicted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::685cf925e5c9393dfaf47e8390b1038a
https://curis.ku.dk/ws/files/199953285/journal.pone.0194609.pdf
https://curis.ku.dk/ws/files/199953285/journal.pone.0194609.pdf
Autor:
Pushpa Saksena, Ib Jarle Christensen, Ida Kappel Buhl, G Carlsson, Peter Buhl Jensen, Yvonne Wettergren, Steen Knudsen, Anders Edsjö, Anker Jon Hansen, Bengt Gustavsson
Publikováno v:
Annals of Oncology. 30:v242
Background No biomarkers predict efficacy of 5-FU for metastatic colorectal cancer (mCRC). A gene expression based drug response predictor (DRP) had been shown to predict benefit of 5-FU in the PETACC-3 cohort [1]. The current study aimed to validate
Autor:
Hella Danoe, Thomas Jensen, Erik Jakobsen, Vesna Glavicic, Jurij Bogovic, Dorte Nielsen, Eva Balslev, Annie Rasmussen, Peter Buhl Jensen, AS Knoop, Bent Ejlertsen, Ida Kappel Buhl, Ulrik Lassen, Joergen Hansen, Ulla Hald Buhl, Sven Tyge Langkjer, Steen Knudsen, Anker Jon Hansen, Mogens Winkel Madsen, Soeren Linnet
Publikováno v:
Hugger Jakobsen, E, Nielsen, D, Danø, H, Linnet, S, Hansen, J, Lassen, U N, Balslev, E, Glavicic, V, Bogovic, J, Knudsen, S, Ejlertsen, B, Søegaard Knoop, A, Buhl, U H, Madsen, M W, Buhl, I K, Hansen, A, Jensen, T, Rasmussen, A, Jensen, P B & Langkjer, S T 2018, ' Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study ', Journal of Clinical Oncology, vol. 36, no. 15 Suppl., e13077 . https://doi.org/10.1200/JCO.2018.36.15_suppl.e13077
e13077Background: In an ongoing, open-label Phase 2 study liposomal cisplatin (LiPlaCis) was evaluated in metastatic breast cancer (mBC) patients selected by a cisplatin-specific mRNA-based drug re...
Autor:
Thomas Jensen, Peter Buhl Jensen, Jon Askaa, Ib Jarle Christensen, Jesper Ravn, Ida Kappel Buhl, Jens Benn Soerensen, Steen Knudsen, Eric Santoni-Rugiu, Alastair Hansen
Publikováno v:
Annals of Oncology. 27:vi411
Autor:
Peter Buhl Jensen, Anker Jon Hansen, Eric Santoni-Rugiu, Jens Benn Soerensen, Ida Kappel Buhl, Thomas Jensen, Steen Knudsen, Jon Askaa, Ib Jarle Christensen, Jesper Ravn
Publikováno v:
Journal of Clinical Oncology. 34:e20007-e20007
e20007Background: This study evaluated the predictive effect of a mRNA-based Drug Response Predictor DRP in the adjuvant setting of non-small cell lung cancer (NSCLC). We apply a mathematical metho...
Autor:
Anker Jon Hansen, Sabine Tejpar, Sarah Gerster, Ida Kappel Buhl, Mauro Delorenzi, Thomas Jensen, Arnaud Roth, Peter Buhl Jensen, Steen Knudsen, Nils Brünner, Fred T. Bosman
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155123 (2016)
PLoS ONE
PloS one, vol. 11, no. 5, pp. e0155123
PLoS ONE
PloS one, vol. 11, no. 5, pp. e0155123
Purpose This study evaluates whether gene signatures for chemosensitivity for irinotecan and 5-fluorouracil (5-FU) derived from in vitro grown cancer cell lines can predict clinical sensitivity to these drugs. Methods To test if an irinotecan signatu